Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 62; no. 1; pp. e1 - e3
Main Authors Coates, Laura C, Garrood, Toby, Gullick, Nicola, Helliwell, Philip, Kent, Toby, Marks, Jonathan, Tillett, William, Kaur-Papadakis, Daljit, Tahir, Hasan, van Haaren, Stijn, McInnes, Iain
Format Journal Article
LanguageEnglish
Published England 23.12.2022
Subjects
Adalimumab - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis, Psoriatic - drug therapy
Heterocyclic Compounds, 3-Ring - therapeutic use
Humans
Treatment Outcome
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/keac388